Clinical trial
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients…
NCT00272662 · Affymax, Industry · Completed
Key facts
| NCT number | NCT00272662 |
|---|---|
| Title | Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy |
| Official title | A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy |
| Lead sponsor | Affymax, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chemotherapy Induced Anemia, Cancer |
| Intervention type | Drug |
| Interventions | peginesatide |
| Enrollment | 60 |
| Start date | Jan 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Jan 9, 2006 |
| Last update posted | Dec 21, 2012 |
| Countries | Czechia, Poland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: